- Home
- NMG vs ESPR Comparison
NMG vs ESPR Comparison
Compare NMG & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMG
- ESPR
- Stock Information
- Founded
- NMG 2011
- ESPR 2008
- Country
- NMG Canada
- ESPR United States
- Employees
- NMG N/A
- ESPR N/A
- Industry
- NMG Other Metals and Minerals
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- NMG Basic Materials
- ESPR Health Care
- Exchange
- NMG Nasdaq
- ESPR Nasdaq
- Market Cap
- NMG 448.1M
- ESPR 534.3M
- IPO Year
- NMG 2017
- ESPR 2013
- Fundamental
- Price
- NMG $2.45
- ESPR $2.85
- Analyst Decision
- NMG Strong Buy
- ESPR Buy
- Analyst Count
- NMG 3
- ESPR 6
- Target Price
- NMG $4.22
- ESPR $6.50
- AVG Volume (30 Days)
- NMG 1.9M
- ESPR 6.7M
- Earning Date
- NMG 11-14-2025
- ESPR 11-06-2025
- Dividend Yield
- NMG N/A
- ESPR N/A
- EPS Growth
- NMG N/A
- ESPR N/A
- EPS
- NMG N/A
- ESPR N/A
- Revenue
- NMG N/A
- ESPR $268,125,000.00
- Revenue This Year
- NMG N/A
- ESPR $18.83
- Revenue Next Year
- NMG N/A
- ESPR N/A
- P/E Ratio
- NMG N/A
- ESPR N/A
- Revenue Growth
- NMG N/A
- ESPR N/A
- 52 Week Low
- NMG $1.22
- ESPR $0.69
- 52 Week High
- NMG $6.06
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- NMG 41.82
- ESPR 54.35
- Support Level
- NMG $2.75
- ESPR $2.80
- Resistance Level
- NMG $3.60
- ESPR $3.01
- Average True Range (ATR)
- NMG 0.42
- ESPR 0.16
- MACD
- NMG -0.12
- ESPR -0.00
- Stochastic Oscillator
- NMG 8.36
- ESPR 55.90
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.